181 related articles for article (PubMed ID: 23551668)
1. Current ways of treating dyslipidemias to prevent atherosclerosis.
Angelico F; Baratta F; Del Ben M
Ther Apher Dial; 2013 Apr; 17(2):125-9. PubMed ID: 23551668
[No Abstract] [Full Text] [Related]
2. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary].
; Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA; Sadikot S; Santos RD; Susekov A; Sy R; Tokgozoglu L; Watts GF; Zhao D;
Clin Investig Arterioscler; 2014; 26(1):33-7. PubMed ID: 24169377
[No Abstract] [Full Text] [Related]
3. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
Catapano AL; Averna M; Faggiano P; Novo S
G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
[No Abstract] [Full Text] [Related]
4. Management of inherited atherogenic dyslipidemias in children.
Guardamagna O; Cagliero P; Abello F
Ther Apher Dial; 2013 Apr; 17(2):150-61. PubMed ID: 23551671
[TBL] [Abstract][Full Text] [Related]
5. Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
Ascaso JF; Millán J; Hernández-Mijares A; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X;
Clin Investig Arterioscler; 2017; 29(2):86-91. PubMed ID: 28185675
[TBL] [Abstract][Full Text] [Related]
6. [Prevention and treatment of atherosclerosis and cardiovascular diseases].
Knobler H; Bitzur R; Gavish D; Rubinstein A; Henkin Y; Chajek-Shaul T; Harats D
Harefuah; 2012 May; 151(5):281-8, 319, 318. PubMed ID: 22844732
[TBL] [Abstract][Full Text] [Related]
7. Treatment of dyslipidaemia in childhood.
Kusters DM; Vissers MN; Wiegman A; Kastelein JJ; Hutten BA
Expert Opin Pharmacother; 2010 Apr; 11(5):739-53. PubMed ID: 20210683
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.
Ascaso JF; Millán J; Hernández-Mijares A; Blasco M; Brea Á; Díaz Á; Pedro-Botet J; Pintó X;
Clin Investig Arterioscler; 2020; 32(3):120-125. PubMed ID: 32291195
[No Abstract] [Full Text] [Related]
9. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version.
Teramoto T; Sasaki J; Ishibashi S; Birou S; Daida H; Dohi S; Egusa G; Hiro T; Hirobe K; Iida M; Kihara S; Kinoshita M; Maruyama C; Ohta T; Okamura T; Yamashita S; Yokode M; Yokote K
J Atheroscler Thromb; 2013; 20(10):733-42. PubMed ID: 23892529
[No Abstract] [Full Text] [Related]
10. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
11. Pediatric lipidology.
Moodie D
Congenit Heart Dis; 2013; 8(4):271-2. PubMed ID: 23875778
[No Abstract] [Full Text] [Related]
12. Atherosclerosis prevention and treatment in children and adolescents.
Oliveira FL; Patin RV; Escrivão MA
Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):513-28. PubMed ID: 20397826
[TBL] [Abstract][Full Text] [Related]
13. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
Reiner Z
Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
[No Abstract] [Full Text] [Related]
14. [Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Kotake H; Oikawa S
Nihon Rinsho; 2006 Nov; 64(11):2074-80. PubMed ID: 17087299
[TBL] [Abstract][Full Text] [Related]
15. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: the Louis F. Bishop Lecture.
Gotto AM
J Am Coll Cardiol; 2005 Oct; 46(7):1219-24. PubMed ID: 16198834
[No Abstract] [Full Text] [Related]
16. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
Olsson AG
Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
[No Abstract] [Full Text] [Related]
17. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
Shoji T; Nishizawa Y
Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
[TBL] [Abstract][Full Text] [Related]
18. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
19. Strategies for treating lipids for prevention: risk stratification models with and without imaging.
Okwuosa TM; Mallikethi-Reddy S; Jones DM
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):295-307. PubMed ID: 24840260
[TBL] [Abstract][Full Text] [Related]
20. [Atherogenic dyslipidemia, underdiagnosed factor for cardiovascular complications].
Aray-Andrade MM; López-Montanero EE; Preciado-Gómez JA
Salud Publica Mex; 2018; 60(4):381-382. PubMed ID: 30137933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
